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Background: The low risk febrile neutropenic patients with Multinational Association for Supportive Care in Cancer
(MASCC) score of more than 20 are recommended to be treated with fluoroquinolone-based oral treatment by the
National Comprehensive Cancer Network (NCCN) guideline. This recommendation relies, at least partially, on the
high sensitivity of the blood culture isolates to fluoroquinolone in clinical trials conducted in Western countries.
Whether this also applies in middle or low income countries like China where antibiotic resistance is becoming
prevalent recently has not been evaluated.
Methods: All the positive blood culture results from January 2010 to December 2013 in the 2 large Chinese cancer
centers were reviewed. The patients were included into the study with the following criteria: febrile neutropenia,
solid tumor or lymphoma, MASCC score >20, positive blood cultures within two days of the onset of fever, and
detailed treatment history.
Results: A total of 38 patients were included in this analysis. Two patients had polymicrobial bacteremia (Enterococcus
faecalis and Flavimonas oryzihabitans). Other isolates included coagulase-negative staphylococcus, micrococcal species,
viridans streptococci, Klebsiella pneumoniae, and Escherichia coli. The majority of the monomicrobial isolates from these
36 patients was Escherichia coli (28 patients, 74%). Notably, in contrast to the high sensitivity to fluoroquinolone from
blood culture of the low risk patients in previous reports in Westen countries, a very high drug resistance was observed:
13 out of 28 Escherichia coli isolates (46%) or 14 out of all 38 positive cultures (37%).
Conclusion: The results warrant further validations in prospective clinical trials in countries where antibiotic resistance
is prevalent to ensure appropriate antibiotic administration.Background
Febrile neutropenia, a serious complication commonly
found in cancer patients receiving chemotherapy and/or
radiotherapy, should be evaluated immediately. The pa-
tients with Multinational Association for Supportive
Care in Cancer (MASCC) score more than 20 can be
categorized as low risk [1]. The current American Society
of Clinical Oncology (ASCO) guideline recommends
immediate quinolone-based oral empiric antibiotic therapy
for these patients [2,3].
This recommendation is based on several reasons: First,
previous phase III trials as well as the observational* Correspondence: wozhangsheng@hotmail.com
1Department of Medical Oncology, Fudan University Shanghai Cancer
Center, Xuhui District, Shanghai, China
2Department of Oncology, Shanghai Medical College, Fudan University, 270
Dongan Road, 200032 Shanghai, China
Full list of author information is available at the end of the article
© 2015 Zhang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.studies have demonstrated the feasibility and success of
oral quinolone-based empiric therapy for the low risk fe-
brile neutropenic patients in some settings [4-9]. Indeed,
the majority (>85%) patients can recover successfully with
this treatment alone. Second, the culture results, especially
the blood culture results showed consistently very low
drug resistance to quinolone (~5%) which supported the
routine use of quinolone-based antibiotic treatment [5,10].
Although the (ASCO) and National Comprehensive
Cancer Network (NCCN) guidelines have been widely
accepted and followed to guide daily practice for clinical
oncologists worldwide, whether these guidelines could
be indiscriminately generalized into the middle and low
income countries like China where the antibiotics are
easily accessible until recently is still debatable [11-13].
The antibiotic consumption per capita in China is nine
times more than that in Western countries. The resultantThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and clinical characteristics of
patients (n = 38)
Characteristic No. %






Solid tumor 27 71
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some other low and middle income countries [14-16].
We collected all positive blood culture results from
January 2010 to December 2013 in two large cancer cen-
ters in China. In this study, the results from 38 patients
whom can be categorized as low risk were analyzed.
Methods
FN definition
Neutropenia was defined as an absolute granulocyte
count <0.5 × 109 cells/L(<500/ul), or <1 × 109 cells/L
(<1,000/ul), expected to fall to <0.5 × 109(<500/ul) within
24 hours, secondary to administration of chemotherapy
and/or radiation within the last 30 days. Fever was de-
fined as an oral (or tympanic)temperature >38.5 once,
or ≥ two occasions (at least 1 hour apart) during the last
12-hour period, and suspected to be the result of
infection.
All the positive blood cultures from January 2010 to
December 2013 in the two large cancer centers (Shanghai
Cancer Center, Fudan University; Cancer Center, The
Affiliated Hospital of Qingdao University Medical College)
were reviewed. The patients were first selected only if they
met the febrile neutropenia criteria and were solid tumor
or lymphoma patients. The patients were also selected if
they have MASCC score >20. The detailed medical files of
each patient were reviewed. Further selections include:
The blood culture should be drawn within two days of the
onset of fever to ensure the reliability of primary infection;
Data regarding overall condition, use of antibiotics, deve-
lopment of serious complications were also reviewed. In
order to ensure the reliability, only bacterial results from
blood instead of those from urine or other sources were
collected and analyzed.
The duration of antibiotics was measured as the number
of days between the dates of the first and last doses of anti-
biotics. The duration of fever was measured from the date
of presentation to date of resolution of fever (oral tem-
perature <38 for a minimum of 24 hours). The duration of
hospitalization was defined as the difference between the
dates of admission and discharge from the hospital, inclu-
sive of both days. The deaths within 30 days of the fever
were viewed as early death and were reviewed to determine
whether they were related to primary infection.
Ethics statement
The independent ethics committees at the Shanghai
Cancer Center of Fudan University and Cancer Center,
The Affiliated Hospital of Qingdao University Medical
College Sed this study. Written informed consent was
waived because this is a retrospective study.
The study was undertaken in accordance with the
ethical standards of the World Medical Association
Declaration of Helsinki.Results
After careful review, a total of 38 patients with bac-
teremia whom can be categorized as low risk were in-
cluded in this study. About a half of the patients were
outpatients at fever onset. 71% patients had solid tumor,
and the remaining patients had lymphoma. Detailed neu-
tropenia and MASCC score profile were listed (Table 1).
Grade 4 neutropenia was present in 37% of the patients;
76% had an MASCC score of 21 to 23, and 24% had a
score of 24 to 26.
In microbiologically documented infections from blood
culture, there were two patients with polymicrobial
bacteremia (Enterococcus faecalis and Flavimonas oryziha-
bitans). These two patients responded to vancomycin-
based antibiotic therapy and they subsequently recovered.
The organisms isolated from other patients included
coagulase-negative Staphylococcus, Micrococcus species,
viridans group streptococci, Klebsiella pneumoniae, and
Escherichia coli (Table 2). The majority of the monomi-
crobial isolates from these 36 patients were Escherichia
coli (28 patients, 74%). There was no early death in the 8
patient with non-Escherichia coli bacteremia. The two
early deaths which were bacteremia-related were both in
the Escherichia coli group: two patients with bacteremia
and development of septic shock died on day 11 and day
14, respectively. Remarkably, in contrast to the high sensi-
tivity to fluoroquinolone from blood culture of the low
Table 2 Bloodstream infection details
Organisms No. of patients Resistance*
Monomicrobial
Escherichia coli 28 13
Micrococcus spp. 2 /
CoNS 3 /
Viridans streptococci 1 /
Klebsiella pneumonia 2 1
Ploymicrobial
Enterococcus faecalis and
Flavimonas oryzihabitans 2 /
Abbreviation: CoNS coagulase-negative Staphylococcus.
*Resistance to fluoroquinolone.
Table 3 Treatment information and outcomes
Outcomes No. %
Clinical deterioration 11 29
Survival at day 30 36 94
Further infection 11 29











Ciprofloxacin and amoxicillin-clavulanate 13 34
Quinolone alone 11 29
Other 14 37
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very high drug resistance was observed: 13 out of 28
Escherichia coli bacteria (46%) or 14 out of all 38 positive
culture (37%). The fluoroquinolone refers to ciprofloxacin
or levofloxacin since these two agents were usually tested
for the drug resistance.
The median duration of antibiotic therapy was 15 days
(range, 9-35 days). The median duration of hospitali-
zation was 9.2 days (range, 5-28 days). The median fever
duration was 4.3 days (range, 2–17 days). About 70% pa-
tients showed clinical improvement, while the remaining
patients showed clinical deterioration. There were two
early death which were related to the primary infection.
About half of the patients received granulocyte colony
stimulating factor (G-CSF). The quinolone based oral
treatment was prescribed in 63% patients: 34% had
ciprofloxacin and amoxicillin-clavulanate and 29% had
quinolone alone. The remaining 37% patients took other
oral antibiotics such as cefaclor (Table 3).
Discussion
Oral regimens for febrile neutropenia have largely relied
on the activity of fluoroquinolone against Gram-negative
bacteria, which may have been decreasing in recent
years. Fluoroquinolone resistance in Gram-negative bac-
teria has been observed in febrile neutropenic patients
in some countries [17-20]. However, this phenomenon
was observed mainly in hematological patients and most
patients cannot be categorized as low risk [19-21].
In the first and the only phase III, placebo-controlled,
randomized trial for MASCC low risk febrile neutro-
penic patients, out of 19 Gram-negative bloodstream
isolates causing primary infection among 333 patients,
there was only one fluoroquinolone-resistant isolate
(rate 5%) [5]. Similar low rate of fluoroquinolone resis-
tance was also corroborated in the previous phase III
trial in the patients who were not strictly categorized as
low risk patients [10].Our study here is one of the few studies which evalua-
ted the low risk febrile neutropenic patients with blood
culture results. The positive rate of blood culture for low
risk febrile neutropenic patients is very low (about 5%),
making collection and analyses of the data are very diffi-
cult [5]. Our result provided the largest data set regar-
ding this topic. In contrast to the previously reported
very low drug resistance to fluoroquinolone in the low
risk febrile neutropenic patients mainly in Western
countries, our study showed that a substantial resistance
in this study, which may raise the caution when refer to
recommendations in the NCCN guideline.
There are several possible reasons for the observed drug
resistance to fluoroquinolone. First, there has always been
one concern regarding the widely used prophylactic quin-
olone for the low risk febrile neutropenia. Antibacterial
prophylaxis might select for microbial resistance, and con-
versely, resistance patterns may affect prophylactic efficacy
[3,9,22,23]. Second, and more importantly, the situation
with respect to overuse of antibiotics and antibiotic resis-
tance in China is severe. The antibiotic consumption per
capita in China is about nine times more than that in
United States. In a study of resistance patterns of several
common bacteria in China in 1999 and 2001, the mean
prevalence of resistance among hospital-acquired infec-
tions was as high as 41% and that among community-
acquired infections was 26% [24]. China also has the
world’s most rapid growth rate of resistance (22% average
growth in a study spanning 1994 to 2000) [14]. These
factors taken together may contribute to the observed
high fluoroquinolone resistance in this study.
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and time to defervescence are longer in our study
compared with those reported in clinical trials. This is
a common observation when comparing outcomes
observed in carefully controlled clinical trials with those
in general oncology practice [12]. Moreover, it can be
also related to the nature of all patients who have
bacteremia in this study and the drug resistance of iso-
lated bacteria. The patients with bacteremia may need more
time for the antibiotic treatment and hospitalization before
they can recover.
Noteworthy, in our study, the prognosis of micro-
biologically documented infections was not severe. The
mortality rate was acceptable, two early death out of 38
patients (rate, 5%) were viewed as primary infection-
related. For the majority of the patients, the antibiotics
were adjusted according to culture result or the empiric
use by the physicians. The empirical use of the asso-
ciation of ceftriaxone and amikacin may have contri-
buted to the overall fair outcome of infectious episodes.
In addition, the frequent use of G-CSF (about half ) in
these patients may have improved outcomes because of
reduced duration of neutropenia.
The results here raised a caution to generalize the
recommendations from ASCO and NCCN guideline to
the low and middle income countries like China [11]. In
the recent years, ASCO has rapidly gained its recogni-
tion among oncologists in China. More and more educa-
tional programs have been introduced for the purpose of
evidence-based medicine. However, most studies, espe-
cially the randomized phase III trials were conducted in
developed countries [13]. The high prevalence of fluoro-
quinolone resistance among bacteria isolates from low
risk febrile neutropenic patients in this study suggests
different antibiotic coverage might be needed.
It was reported recently that the efficacy of once-daily,
oral levofloxacin monotherapy was tested in a pilot
study in Chinese patients with solid tumor and low-risk
febrile neutropenia [25]. They demonstrated that oral
levofloxacin could be effective for the patients. However,
this study only has a limited sample size: the efficacy
population was base on 41 patients per protocol. More
importantly, blood culture results from these patients re-
vealed there was no positive culture in this study. This
suggests the patient population in this study might be
different from that in our study. Only future large pro-
spective, multicenter, phase III studies could establish
the role of this oral antibiotic for low-risk, febrile neu-
tropenic patients with solid tumor in areas where there
is prevalent antibiotic resistance.
Our study has its intrinsic limitations of retrospective
studies. The patient population from the two compre-
hensive cancer centers in China may not reflect patient
polulations in community hospitals. It is also possiblethat patients who present to referral institutions may
have more complex diseases. Due to the selection bias,
the resistance to quinolone may have been over- or
under-estimated, which need to be validated in the
future prospective clinical trials.
Conclusions
The high sensitivity of the blood culture isolates to fluo-
roquinolone from low risk febrile neutropenic patients is
the basis for quinolone-based treatment which was rec-
ommended by NCCN guideline. A total of 38 low risk
patients with positive blood cultures (this is the biggest
data set regarding this topic.) were included in this ana-
lysis. A very high drug resistance was observed: 13 out
of 28 Escherichia coli isolates (46%) or 14 out of all 38
positive cultures (37%). The results warrant further vali-
dations in prospective clinical trials in countries where
antibiotic resistance is prevalent to ensure appropriate
antibiotic administration.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
lY and WQ participated in the clinical data collecting and drafted the
manuscript. ZS performed the statistical analysis. ZS and HX conceived of
the study, participated in its design and coordination. All authors read and
approved the final manuscript.
Acknowledgements
We gratefully thank the staff members in the Department of Medical
Oncology at Fudan University Cancer Center for their suggestion and
assistance.
Author details
1Department of Medical Oncology, Fudan University Shanghai Cancer
Center, Xuhui District, Shanghai, China. 2Department of Oncology, Shanghai
Medical College, Fudan University, 270 Dongan Road, 200032 Shanghai,
China. 3Department of Clinical Laboratory, The Affiliated Hospital of Qingdao
University Medical College, Shinan, Qingdao, Shandong, China. 4Department
of Clinical Laboratory, Shanghai Cancer Center, Fudan University, Shanghai,
China.
Received: 23 October 2014 Accepted: 30 January 2015
References
1. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile
neutropenia in solid tumours and lymphomas using the Multinational
Association for Supportive Care in Cancer (MASCC) risk index: feasibility and
safety in routine clinical practice. Support Care Cancer. 2008;16(5):485–91.
2. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al.
Antimicrobial prophylaxis and outpatient management of fever and
neutropenia in adults treated for malignancy: American Society of Clinical
Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794–810.
3. Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Cumsille MA, et al.
Early hospital discharge followed by outpatient management versus
continued hospitalization of children with cancer, fever, and neutropenia at
low risk for invasive bacterial infection. J Clin Oncol. 2004;22(18):3784–9.
4. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of
patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol.
2007;25(30):4821–8.
5. Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, et al. Oral
antibiotics for fever in low-risk neutropenic patients with cancer: a
double-blind, randomized, multicenter trial comparing single daily
Zhang et al. BMC Cancer  (2015) 15:42 Page 5 of 5moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid
combination therapy–EORTC infectious diseases group trial X. J Clin Oncol.
2013;31(9):1149–56.
6. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al.
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score
predictive for complications. J Clin Oncol. 2006;24(25):4129–34.
7. Rolston KV, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault
RL, et al. Once daily, oral, outpatient quinolone monotherapy for low-risk
cancer patients with fever and neutropenia: a pilot study of 40 patients
based on validated risk-prediction rules. Cancer. 2006;106(11):2489–94.
8. Sung L, Feldman BM, Schwamborn G, Paczesny D, Cochrane A, Greenberg
ML, et al. Inpatient versus outpatient management of low-risk pediatric
febrile neutropenia: measuring parents’ and healthcare professionals’
preferences. J Clin Oncol. 2004;22(19):3922–9.
9. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, et al.
Outcomes and cost of outpatient or inpatient management of 712 patients
with febrile neutropenia. J Clin Oncol. 2008;26(4):606–11.
10. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al.
A double-blind comparison of empirical oral and intravenous antibiotic
therapy for low-risk febrile patients with neutropenia during cancer
chemotherapy. N Engl J Med. 1999;341(5):305–11.
11. Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer Sr PJ. Role of American
Society of Clinical Oncology in low- and middle-income countries. J Clin
Oncol. 2011;29(22):3097–102.
12. Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, et al. Safety of
early discharge for low-risk patients with febrile neutropenia: a multicenter
randomized controlled trial. J Clin Oncol. 2011;29(30):3977–83.
13. Wang J. Evidence-based medicine in China. Lancet. 2010;375(9714):532–3.
14. Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China–a
major future challenge. Lancet. 2009;373(9657):30.
15. Wang L, Wang Y, Jin S, Wu Z, Chin DP, Koplan JP, et al. Emergence and
control of infectious diseases in China. Lancet. 2008;372(9649):1598–605.
16. Radyowijati A, Haak H. Improving antibiotic use in low-income countries: an
overview of evidence on determinants. Soc Sci Med. 2003;57(4):733–44.
17. Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, et al.
Differences in the proportions of fluoroquinolone-resistant Gram-negative
bacteria isolated from bacteraemic children with cancer in two Italian
centres. Clin Microbiol Infect. 2005;11(6):505–7.
18. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E,
et al. Recent changes in bacterial epidemiology and the emergence of
fluoroquinolone-resistant Escherichia coli among patients with haematological
malignancies: results of a prospective study on 823 patients at a single
institution. J Antimicrob Chemother. 2008;61(3):721–8.
19. Cometta A, Marchetti O, Calandra T, Bille J, Kern WV, Zinner S. In vitro
antimicrobial activity of moxifloxacin against bacterial strains isolated from
blood of neutropenic cancer patients. Eur J Clin Microbiol Infect Dis.
2006;25(8):537–40.
20. Zaidi Y, Hastings M, Murray J, Hassan R, Kurshid M, Mahendra P. Quinolone
resistance in neutropenic patients: the effect of prescribing policy in the UK
and Pakistan. Clin Lab Haematol. 2001;23(1):39–42.
21. Zemkova M, Kotlarova J, Merka V, Cermak P, Vlcek J, Jebavy L. Emergence of
fluoroquinolone resistance in Escherichia coli isolates at the department of
clinical hematology. New Microbiol. 2007;30(4):423–30.
22. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi
SA, et al. Prevention of chemotherapy-induced febrile neutropenia by
prophylactic antibiotics plus or minus granulocyte colony-stimulating factor
in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol.
2005;23(31):7974–84.
23. Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, et al.
Predicting adverse events in children with fever and chemotherapy-induced
neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol.
2010;28(12):2008–14.
24. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a
global threat: evidence from China, Kuwait and the United States. Global
Health. 2006;2:6.
25. He L, Zhou C, Zhao S, Weng H, Yang G. Once-daily, oral levofloxacin
monotherapy for low-risk neutropenic fever in cancer patients: a pilot
study in China. Anticancer Drugs. 2015;26(3):359–62.
doi:10.1097/CAD.0000000000000187.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
